After posting its draft statement for comment earlier this year, the US Preventive Services Task Force has now released its final recommendation statement on screening for obstructive sleep apnea in asymptomatic people ages 18 and older.
SomnoMed details its journey from its emergence through present day, including its new chapter that will change the oral appliance industry.
New data from Signifier demonstrates real-world patient adherence of eXciteOSA over the first six weeks of treatment.
People with more severe sleep apnea are at greater risk of developing venous thromboembolisms—a potentially life-threatening condition.
Read More
A new study presented at ERS specifies links between obstructive sleep apnea and cognitive decline among several demographics.
Read More
Dronabinol, synthetic THC, shows promise for the treatment of sleep apnea, and new advances from pharmaceutical companies suggest how it can be optimized.
Read More
New research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read More
A large study on obstructive sleep apnea and cancer risk finds severity index differences between patients with and without cancer.
Read More
An analysis from Flinders University’s Adelaide Institute for Sleep Health looked at the potential danger of co-morbid insomnia and sleep apnea.
Read More
Treatment for OSA typically starts downstream with the throat, instead of upstream in the nose, the first site of breathing difficulty.
Read More
A study of oral appliances analyzed during DISE provides insight into their mechanism of action on upper airway morphology.
Read More
People ages 65 and older face unique sleep apnea therapy challenges. Experts discuss common CPAP issues among seniors, as well as suggest strategies to promote adherence.
Read More
New research suggests that many more OSA patients may clinically benefit from maxillomandibular advancement than sleep specialists assume.
Read More
SomnoMed provides updates on Rest Assure, including the completion of its second patient validation study.
Read More
Sommetrics is advancing activities aimed at obtaining US Food and Drug Administration (FDA) market clearance for its flagship product, aerSleep II, which is targeted for the treatment of obstructive sleep apnea in those unable to use CPAP therapy.
Read More
New launches and upcoming plans from ZOLL Respicardia, Inspire Medical, and LivaNova make patient data more accessible and trackable.
Read More
This full-body MRI approval expands the Inspire use labeling that previously allowed only head, neck, and extremity MRI scans.
Read More
Apnimed’s AD109 has the potential to be the first oral pharmacologic that treats OSA airway obstruction at night.
Read More